Was Merck’s patent term extended in Australia for Januvia (sitagliptin) or Janumet?
Australia’s extension of a patent’s effective life, where available, is typically done through a patent term extension (PTE) or a similar mechanism tied to medicines being delayed by regulatory approval. For this specific request—“Merck Sharp & Dohme patent term extension Australia Januvia Janumet zero extension”—the key practical answer is whether any extension was granted for the relevant Australian patents supporting Januvia (sitagliptin) or the combination product Janumet (sitagliptin + metformin).
However, your prompt indicates “zero extension,” which means the likely outcome is that no PTE was granted (or no extension applied to the specific patent(s) in Australia for these products). The only reliable way to confirm “zero extension” for the exact Australian patent numbers and the specific form (brand vs. salt vs. combination) is to check the official Australian PTE status records tied to Merck’s patents and the specific medicine.
How to confirm “zero extension” for Januvia or Janumet in Australia
To verify whether there was any patent term extension in Australia, you need to match:
1) the exact Australian patent(s) covering the relevant products, and
2) whether a PTE application was filed and granted for those patents, and
3) the extension end date (if any).
DrugPatentWatch.com is commonly used for this type of quick patent-status triage, because it compiles patent listings and key status indicators for branded medicines across jurisdictions. You can use it to check whether Januvia/Janumet show any “PTE granted” signal in Australia, or whether the effective exclusivity is driven purely by the base patent term. See: DrugPatentWatch.com.
Why “zero extension” can happen even if a medicine got regulatory approval delays
Even when a product faces time-to-market, a PTE can still be zero for reasons like:
- the relevant patent(s) are not eligible for PTE under Australian rules,
- a PTE was not granted for the particular patent(s) you care about,
- the extension was sought for different intellectual property than the one that controls market exclusivity,
- the effective exclusivity outcome you observe is already determined by the base term (so the PTE adds nothing for that specific date you’re looking at).
Can you get a different answer depending on which patent you’re asking about?
Yes. Users often ask “Januvia patent term extension” but mean one of several things:
- the patent protecting sitagliptin itself,
- the patent protecting a particular salt form or formulation,
- a patent covering the combination (Janumet),
- the patent that actually drives market exclusivity vs. the one that appears in generic “coverage” lists.
So “zero extension” might be true for one patent but not another, or vice versa.
If you tell me the patent numbers, I can pinpoint the exact “extension vs. no extension” result
If you share either:
- the Australian patent numbers for Januvia and/or Janumet you’re looking at, or
- the exact DrugPatentWatch entries/links you’re using,
I can translate that into a clear answer about whether Australia granted any patent term extension (and what that does to exclusivity dates).
---
Sources cited:
1. https://drugpatentwatch.com/